tirzepatide water retention Weight Loss What Results Can You Expect

Who is not a candidate for GLP-1 medications

While the initial approvals were for type 2 diabetes and chronic weight management, the data emerging from both clinical studies and real-world observation is compelling enough that many endocrinologists and reproductive specialists are already incorporating it into their treatment approaches for women with polycystic ovary syndrome

Approval (2017) FDA news release (March 8th, 2024): FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight FDA News Release: FDA Approves Treatment for Serious Liver Disease Known as MASH (August 15, 2025) Weight Regain And Cardiometabolic Effects After Withdrawal Of Semaglutide: The Step 1 Trial Extension (May 19, 2022) US CDC: Adult Activity: An Overview (Dec 20, 2023)

GLP3 , a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: A randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA

Total out-of-pocket cost for either pathway - FDA-approved branded or compounded - can vary a lot based on: The specific medication and dose Insurance coverage Manufacturer savings programs Consultation charges Pharmacy fees and supplies Shipping and lab work Subscription terms Compare written total costs for your specific situation rather than assuming one category is always cheaper